Funding for this research was provided by:
Janssen Pharmaceuticals
Article History
Received: 24 January 2019
Accepted: 26 July 2019
First Online: 7 August 2019
Ethics approval and consent to participate
: The European NHWS was reviewed and granted exemption status by the Pearl Institutional Review Board (Indianapolis, IN; 17-KANT-141) prior to participant recruitment. All respondents provided written informed consent. The NHWS is part of the Kantar patient-centered research program (PaCeR) and data are not publicly available.
: All respondents viewed an on-line informed consent form and indicated their consent to participate prior to responding to the survey.
: TRD and BR are full-time employees of Janssen-Cilag. DHJ is employed by Kantar Health, which received fees from Janssen-Cilag for access to survey data, analysis, and reporting.